Search
Suvecaltamide
go.drugbank.com/drugs/DB19139InvestigationalSuvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).
Synonyms: 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)benzeneacetamide, Benzeneacetamide, 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)-HSV-2 theracine
go.drugbank.com/drugs/DB05811ExperimentalHSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
APT3111
go.drugbank.com/drugs/DB06390ExperimentalAPT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).
OT-551
go.drugbank.com/drugs/DB05650InvestigationalOT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye.
Iocarmic acid
go.drugbank.com/drugs/DB13755ExperimentalCategories: Compounds used in a research, industrial, or household settingPPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
TPI-ASM8
go.drugbank.com/drugs/DB05572InvestigationalTPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.
Dacetuzumab
go.drugbank.com/drugs/DB12589InvestigationalIt is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse.
Lucitanib
go.drugbank.com/drugs/DB11845InvestigationalLucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.
Dihydrocapsiate
go.drugbank.com/drugs/DB15398InvestigationalDihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).